SCHEMBL4900818

SCHEMBL4900818

O=C(Nc1nc2ccccc2[nH]1)N1CCCCc2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
CYP3A4 P08684 1/20 0.51
SMN1; SMN2 Q16637 6/20 0.51
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.51
POLB P06746 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
HTT P42858 1/20 0.51
MAPT P10636 1/20 0.50
USP2 O75604 1/20 0.49
PKM P14618 2/20 0.49
TP53 P04637 2/20 0.49
MAOB P27338 1/20 0.49
ADORA2A P29274 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214928 0.79 NPC1 (0.43) LMNASMN1; SMN2NPC1RAB9APOLB
SCHEMBL1535706 0.78 LMNA (0.63) LMNACYP3A4SMN1; SMN2NPC1RAB9A
SCHEMBL4867471 0.77 TP53 (0.81) LMNASMN1; SMN2NPC1RAB9APOLB
SCHEMBL4895053 0.76 TP53 (0.64) LMNASMN1; SMN2NPC1RAB9APOLB
SCHEMBL4869023 0.76 TP53 (0.78) LMNASMN1; SMN2NPC1RAB9APOLB
SCHEMBL213978 0.74 NPC1 (0.45) LMNACYP3A4SMN1; SMN2NPC1RAB9A
SCHEMBL4867294 0.74 NOTUM (0.62) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL4863076 0.74 MAPT (0.69) LMNASMN1; SMN2NPC1RAB9APOLB
SCHEMBL4869055 0.74 MEN1 (0.60) LMNASMN1; SMN2NPC1RAB9APOLB
SCHEMBL3096679 0.73 ALDH1A1 (0.68) LMNASMN1; SMN2NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 LMNA 2162/4885CYP3A4 1174/4885SMN1; SMN2 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.